Literature DB >> 19107650

Intestinal bacteria and inflammatory bowel disease.

Sandra Macfarlane1, Helen Steed, George T Macfarlane.   

Abstract

Crohn's disease (CD) and ulcerative colitis (UC) are the two principal forms of inflammatory bowel disease (IBD). Animal studies show that bacteria are involved in the etiology of IBD, and much is now known about the inflammatory processes associated with CD and UC, as well as the underlying genetic, environmental, and lifestyle issues that can affect an individual's predisposition to these diseases. However, while a number of candidate microorganisms have been put forward as causative factors in IBD, the primary etiologic agents are unknown. This review discusses the potential role of luminal and mucosal microbial communities in the etiology of IBD, and outlines studies that have been made using a variety of biotherapeutic therapies, involving the use of antibiotics, probiotics, prebiotics, and synbiotics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19107650     DOI: 10.1080/10408360802485792

Source DB:  PubMed          Journal:  Crit Rev Clin Lab Sci        ISSN: 1040-8363            Impact factor:   6.250


  28 in total

Review 1.  Th17 cells: interactions with predisposing factors in the immunopathogenesis of inflammatory bowel disease.

Authors:  Ali Raza; Wajeeha Yousaf; Ralph Giannella; Mohamed Tarek Shata
Journal:  Expert Rev Clin Immunol       Date:  2012-02       Impact factor: 4.473

2.  Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease-associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation.

Authors:  Yume Nguyen; Abed Al-Lehibi; Elizabeth Gorbe; Ellen Li; Michael Haagenson; Tao Wang; Stephen Spellman; Stephanie J Lee; Nicholas O Davidson
Journal:  Blood       Date:  2010-02-22       Impact factor: 22.113

3.  Epstein-Barr virus replication linked to B cell proliferation in inflamed areas of colonic mucosa of patients with inflammatory bowel disease.

Authors:  Sumathi Sankaran-Walters; Kanat Ransibrahmanakul; Irina Grishina; Jason Hung; Enrique Martinez; Thomas Prindiville; Satya Dandekar
Journal:  J Clin Virol       Date:  2010-10-28       Impact factor: 3.168

4.  Association of dietary type with fecal microbiota in vegetarians and omnivores in Slovenia.

Authors:  Bojana Bogovič Matijašić; Tanja Obermajer; Luka Lipoglavšek; Iztok Grabnar; Gorazd Avguštin; Irena Rogelj
Journal:  Eur J Nutr       Date:  2013-10-31       Impact factor: 5.614

5.  Identification of microbiota dynamics using robust parameter estimation methods.

Authors:  Matthias Chung; Justin Krueger; Mihai Pop
Journal:  Math Biosci       Date:  2017-10-10       Impact factor: 2.144

6.  Rifaximin in the treatment of inflammatory bowel disease.

Authors:  Mario Guslandi
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

Review 7.  Escherichia coli Pathobionts Associated with Inflammatory Bowel Disease.

Authors:  Hengameh Chloé Mirsepasi-Lauridsen; Bruce Andrew Vallance; Karen Angeliki Krogfelt; Andreas Munk Petersen
Journal:  Clin Microbiol Rev       Date:  2019-01-30       Impact factor: 26.132

8.  Introducing W.A.T.E.R.S.: a workflow for the alignment, taxonomy, and ecology of ribosomal sequences.

Authors:  Amber L Hartman; Sean Riddle; Timothy McPhillips; Bertram Ludäscher; Jonathan A Eisen
Journal:  BMC Bioinformatics       Date:  2010-06-12       Impact factor: 3.169

9.  Effects of antibiotics on bacterial species composition and metabolic activities in chemostats containing defined populations of human gut microorganisms.

Authors:  Dorothy F Newton; Sandra Macfarlane; George T Macfarlane
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

10.  Human gut microbiome adopts an alternative state following small bowel transplantation.

Authors:  Amber L Hartman; Denver M Lough; Dinesh K Barupal; Oliver Fiehn; Thomas Fishbein; Michael Zasloff; Jonathan A Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.